Edition:
United Kingdom

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

16.25USD
11 Dec 2017
Change (% chg)

$-0.45 (-2.69%)
Prev Close
$16.70
Open
$16.82
Day's High
$16.87
Day's Low
$16.23
Volume
177,932
Avg. Vol
325,974
52-wk High
$21.94
52-wk Low
$8.14

Select another date:

Wed, Oct 25 2017

FDA declines to approve PTC's Duchenne drug

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

UPDATE 1-FDA declines to approve PTC's Duchenne drug

Oct 25 The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

FDA declines to approve PTC's Duchenne Muscular Dystrophy drug

Oct 25 The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

UPDATE 2-PTC Therapeutics Duchenne drug may work, data inconclusive -FDA panel

Sept 28 PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

FDA panel: PTC Therapeutics Duchenne drug data inconclusive

Sept 28 PTC Therapeutics' experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

FDA pours cold water on PTC Therapeutics' Duchenne drug application

PTC Therapeutics Inc has failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said on Tuesday, dealing a blow to the company's years-long effort to bring the drug to market.

UPDATE 3-FDA pours cold water on PTC Therapeutics' Duchenne drug application

Sept 26 PTC Therapeutics Inc has failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said on Tuesday, dealing a blow to the company's years-long effort to bring the drug to market.

BRIEF-PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing‍​

* Files for potential mixed shelf; size not disclosed - SEC filing‍​ Source text : (http://bit.ly/2xgQ4YT) Further company coverage:

BRIEF-PTC Therapeutics qtrly loss per share $0.44

* Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​

Select another date: